Organon stock
OGNNYSEOrganon & Co., HealthcareISIN US68622V1061
59Score 59 out of 100, Neutral
Price and trend
85 / 100
Price history
+80% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 70).
The price is at its 52-week high. Largest decline in 5 years: 86% (March 2022 to March 2026).
Chart figures for advanced users
- SMA 50$13.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.70
- The lowest closing price of the last twelve months.
- Resistance$13.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Organon & Co. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $3.65B, is number 26 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6.22B (down 2.9% year on year) and earnings of $187M (down 78.4%).
- For fiscal 2026, analysts expect on average revenue of $6.14B (down 1.3%) and adjusted earnings per share of $3.35 (down 8.5%).
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 289 of 714 in Healthcare, median 53.
- Our model puts fair value at $31.17, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 317% of earnings over the last 12 months.Fundamentals 85
- Consistently profitableProfit in all 9 fiscal years from 2017 to 2025.Fundamentals 85
Weaknesses
- High debtDebt 7.17 times equity (latest quarter), Drug Manufacturers (General) median 1.2.Stability 30
- Earnings per share fallingDown 39% a year since 2020.Growth 12
- Interest barely coveredOperating profit covers interest only 1.8 times.Stability 30
Its standout strengths are valuation and fundamentals, while stability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
What lowers it
- solid fundamentals
- low growth grade (crashed less often in the backtest)
- price near its 52-week high
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $22.27 and expensive above $51.96 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $25.95, at 7.8% it would be $39.01.
Possible value trap: looks cheap, but high risk, weak growth.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 3.2% on the twelve months before. Revenue has declined since 2017 (-6% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating 21%, net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 30 Oct 2026EPS reported $0.94 (expected $0.88)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.350.0%
- Revenue
- $6.14B0.0%
- Earnings per share
- $3.630.0%
- Revenue
- $6.36B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $200,307 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Drinane Juliana PapaSale
5 Aug 2026, Head of Mfg & Supply
- Shares
- 14,761
- Price
- $13.57
- Value
- $200,307
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Organon
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Daiichi Sankyo4568.T $31.7B71
- Astellas Pharma4503.T $29.67B87
- OrionORNBV.HE $16.06B86
- CSPC Pharmaceutical Group1093.HK $12.4B79
- Zhangzhou Pientzehuang Pharmaceutical.600436.SS $11.78B58
- GrifolsGRF.MC $8.69B66
- Ono Pharmaceutical4528.T $7.16B73
- VirbacVIRP.PA $3.34B68
ETFs that hold Organon
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.20% | 0.30% | €2.28B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.16% | 0.30% | €944.34M |
| Franklin U.S. Equity UCITS ETFFLXU | 0.11% | 0.20% | €55.89M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.09% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.07% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| Invesco RAFI US Fundamental Value UCITS ETF6PSA | 0.02% | 0.39% | €1.23B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.